HUVEC invasion and angiogenesis in the matrigel plug assay were activated by S100A10, while AXL inhibition reduced tumor progression and vessel density in ccRCC tumor xenografts and PDX models [40]. This evidence concerns the gene S100A10 and nonpapillary renal cell carcinoma.